<DOC>
	<DOCNO>NCT01131845</DOCNO>
	<brief_summary>This single-center , open-label , single-dose evaluation 1 mg UT-15C SR pharmacokinetics , safety , tolerability subject normal , mild , moderate end stage renal disease ( ESRD ; dialysis ) . Subjects ESRD group receive 2 dos UT-15C SR , separate 14 day . One dose give 4 hour prior dialysis , dose give end dialysis . Pharmacokinetic sample take immediately prior dose 0.5 , 1 , 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 24 , 30 , 36 , 42 48 hour post dose . Additionally , subject ESRD sample take 60 hrs post dose .</brief_summary>
	<brief_title>The Effect Renal Impairment Pharmacokinetics Oral Treprostinil</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Male female volunteer ESRD ( require dialysis ) , moderate ( creatinine clearance ; CrCL = 3050 mL/min ) , mild ( CrCL = 5080 mL/min ) normal renal function ( control group ; ( CrCL &gt; 80 mL/min ) ) may enrol . Eligible subject 1879 year age BMI 18 40 kg/m2 take chronic nonsteroidal antiinflammatory drug ( NSAIDs )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>